Research Article
Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome
Table 1
Baseline characteristics of the study population.
| | Variables | Total(n=459) | NPR
(n=275) | HPR
(n=184) | P |
| | Age (years) | 59.58±10.28 | 59.35±10.47 | 59.93±10.00 | 0.551 | | Gender (male)n() | 350(76.3%) | 229(83.3%) | 121(65.8%) | <0.001 | | BMI (kg/m2) | 26.15±3.64 | 25.94±3.38 | 26.32±4.01 | 0.318 | | Risk factor n() | | | | | | Hypertension | 264(57.5%) | 150(54.5%) | 114(62.0%) | 0.115 | | DM | 149(32.5%) | 94(34.2%) | 55(29.9%) | 0.336 | | Dyslipidemia | 189(41.2%) | 117(42.5%) | 72(39.1%) | 0.466 | | Previous PCI | 85(18.5%) | 52(18.9%) | 33(17.9%) | 0.792 | | Current smoking | 168(36.6%) | 110(40.0%) | 58(31.5%) | 0.065 | | Concomitant medications() | | | | | | Statin | 454(98.9%) | 272(98.9%) | 182(98.9%) | 0.997 | | ACEI/ARB | 305(66.4%) | 190(70.2%) | 112(60.9%) | 0.069 | | β-blocker | 381(83.0%) | 224(81.5%) | 157(85.3%) | 0.279 | | PPI | 294(64.1%) | 185(67.5%) | 109(58.9%) | 0.060 | | PCI due to ACS() | 331(72.1%) | 196(71.3%) | 135(73.4%) | 0.623 | | Laboratory measurement | | | | | | Creatinine clearance(mL/min)∗ | 88.51(71.30,109.28) | 88.35(70.32,108.19) | 89.35(72.30,110.74) | 0.670 | | Glucose(mg/dl)∗ | 5.54(5.02,6.84) | 5.51(4.99,6.70) | 5.57(5.07,7.17) | 0.386 | | Triglyceride(mmol/L)∗ | 1.48(1.05,2.11) | 1.48(1.03,2.05) | 1.48(1.07,2.21) | 0.408 | | Cholesterol(mmol/L) | 4.11±1.01 | 4.13±0.95 | 4.09±1.11 | 0.105 | | HDL(mmol/L)∗ | 0.95(0.80,1.09) | 0.95(0.80,1.08) | 0.94(0.81,1.11) | 0.703 | | LDL(mmol/L) | 2.49±0.87 | 2.52±0.81 | 2.45±0.96 | 0.055 | | PLT(×109/L) | 212.9±56.0 | 212.0±54.6 | 214.5±58.2 | 0.063 |
|
|
These risk factors were not in accord with normal distribution. |
